News Genmab axes development of AXL-targeting cancer drug enapota... Genmab has axed development of its pipeline cancer drug enapotamab vedotin after it failed to show enough activity in a proof-of-concept trial.
News BerGenBio raises 45 million euros for COVID-19 drug developm... Norway’s BerGenBio has raised 500 million Norwegian kroner – around $45.4 million euros – in an oversubscribed private placement to develop its pipeline that includes a potential COVID-19 t
News UK initiative aims to cut COVID-19 drug development to a few... A new UK trial initiative aims to cut the design phase of clinical studies for potential COVID-19 drugs from around 18 months to a few weeks.
News FDA follows experts' advice and blocks Capricor DMD therapy The FDA has dashed Capricor's hope of getting approval for its cell therapy for Duchenne muscular dystrophy, wreaking havoc with its share price.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.